California Corporate M&A in 2026: Innovation, Regulation, and Opportunity

Introduction

California remains the epicentre of American innovation, and in 2026, the state’s corporate M&A landscape reflects both the dynamism and the complexity of its leading industries. From the AI start-ups reshaping venture capital, to the life sciences companies attracting billions in strategic investment, to the entertainment, sports and media platforms redefining how content is created and consumed, California-based companies continue to command disproportionate attention from investors, acquirers, and regulators alike.

The deal environment in California in 2026 is more robust than it has been in years, and the stage is set for sustained activity across sectors. Yet the market is not without its challenges. Heightened regulatory scrutiny ‒ from antitrust enforcement to state-level healthcare transaction oversight to evolving privacy regimes ‒ continues to shape deal structures, timelines, and risk allocation. At the same time, the concentration of technology, life sciences, and media companies in California generates both substantial premiums and elevated execution expectations.

This article examines four key areas defining California’s corporate M&A market in 2026:

• the venture capital and AI financing landscape;
• developments in M&A and private equity;
• trends in life sciences deal making; and
• the evolving entertainment, sports, and media sector.

Venture capital and AI

Venture capital investment in AI continues to reshape both the technology landscape and the financing environment that supports it. Over the past couple of years, several distinct trends have emerged, reflecting not only the transformative potential of AI but also the capital-intensive and highly competitive nature of the sector. For investors, entrepreneurs and legal advisors, understanding these dynamics is critical.

The rise of AI early-stage megarounds

One of the most notable developments has been the continued prevalence of seed and early-stage “megarounds” of AI start-ups, often exceeding USD100 million and minting new unicorns at or shortly after inception. Historically, financings of these sizes were generally reserved for later-stage companies with proven technologies and revenue models. Today, however, investors are deploying substantial capital, sometimes as early as at inception, effectively underwriting both product development and market positioning from day one.

These megarounds show a clear investor preference for “AI-native” companies. AI-native companies are those built from day one around AI capabilities, rather than those that incorporate AI as an incremental feature layered onto existing technologies and products. The primary value proposition of an AI native company depends on its AI technology (eg, generating content, making predictions, automating decisions), and its core product or service would not function (or would not exist) without AI. Venture capital firms are increasingly focused on companies developing proprietary models, infrastructure, or deeply integrated AI-driven solutions with capital flowing into a range of verticals, including legal, healthcare, financial services, manufacturing, data platforms, cloud infrastructure and cybersecurity.

Underlying this investment behaviour is a widely held belief in a “first-mover advantage” dynamic within AI markets. The high cost of model development, the importance of access to large-scale datasets, and the reinforcing effects of user adoption all contribute to strong network and scale advantages. Investors are therefore incentivised to back perceived category leaders early and aggressively, rather than diversify across multiple smaller bets. This dynamic has fuelled an AI “arms race,” with venture capital firms, strategic investors and even sovereign-backed funds committing unprecedented sums to foundational models, AI infrastructure, developer tools and application-layer companies.

In parallel, larger, well-capitalised AI companies are increasingly acquiring smaller AI-native start-ups both to accelerate product development and to secure talent and proprietary technology. This consolidation trend is likely to continue, particularly as competitive pressures intensify.

Liquidity constraints and evolving exit pathways

While capital inflows into AI have surged, liquidity and exit opportunities have not kept pace. The long-anticipated reopening of the IPO market remains limited, with only a small number of technology listings successfully reaching public markets. Many AI companies are taking preparatory steps, including strengthening governance structures, enhancing financial reporting and engaging with underwriters, but are ultimately deferring public offerings in light of market volatility and valuation uncertainty.

As a result, companies are operating with longer timelines to exit, often supported by large private financing rounds that extend their runway. This has contributed to the growth of secondary markets as an alternative liquidity mechanism. Dedicated secondary funds have proliferated, providing opportunities for early investors, founders and employees to monetise portions of their holdings without requiring a full exit event. Large tender offers and other structured liquidity programmes have also become more common, with some transactions reaching substantial scale. These mechanisms allow companies to address internal liquidity pressures (particularly among employees holding significant equity). For legal advisors, these transactions present unique considerations, including compliance with securities laws, information parity and full and fair disclosure, valuation fairness and the co-ordination of multiple stakeholder interests.

Another notable development is the growing presence of private equity growth funds in the venture ecosystem. Traditionally focused on more mature companies, these funds are now actively participating in late-stage venture and even earlier-stage financings. Their involvement brings larger check sizes, a focus on operational scalability and, in some cases, different governance expectations. In addition, these investors are often focused on the M&A path to liquidity, and as such the PE growth equity investment is the first step toward an alternative to the IPO as the defining value realisation event for VC-backed entrepreneurs and their companies. This convergence of venture capital and private equity is reshaping deal structures and negotiation dynamics across the market.

Looking ahead

Taken together, these trends point to a venture capital environment that is both highly competitive and evolving. The concentration of capital in a relatively small number of AI leaders, the persistence of large early-stage financings and the continued reliance on private markets for liquidity all suggest that traditional venture models are being redefined. For companies, the implications are significant: access to capital remains robust for those perceived as category-defining, but expectations around growth, defensibility and execution are correspondingly higher. For investors, the challenge lies in balancing the pursuit of outsized returns against the risks inherent in a rapidly consolidating and capital-intensive sector. For entrepreneurs, the environment presents both opportunity and pressure: while capital is available for compelling, differentiated visions, founders must demonstrate clear paths to sustainable growth, strong unit economics, and the ability to execute in an increasingly competitive and scrutinised market. For legal practitioners, the landscape demands careful navigation of increasingly complex financing structures, secondary transactions, uniquely structured M&A, and cross-border considerations.

M&A and private equity

As discussed below, deals involving California-based companies are being shaped by a mix of sector concentration and regulatory intensity that differentiates California from many other markets.

AI and diligence expectations

Across the AI, software, data and cybersecurity companies prevalent in California, buyers are valuing not only growth, but also the defensibility of data assets, model training inputs and product differentiation. This shift has real implications for deal execution, including diligence intensity and liability assessment. On diligence intensity, buyers are demanding deeper diligence around data provenance, open-source compliance, model training practices, cybersecurity controls and AI governance frameworks, particularly where value is tied to proprietary or regulated datasets. On liability assessment, buyers find that product claims, IP chain-of-title, consumer disclosures and exposure under privacy and unfair competition regimes are receiving earlier and more technical scrutiny.

In short, the concentration of companies in these sectors in California is generating substantial premiums in the market, but it is also raising the execution bar. And targets that cannot withstand a targeted commercial and legal diligence review will face valuation pressure or elongated sale processes.

In PE M&A, exits are returning, but the routes are evolving

Sponsors continue to manage a meaningful inventory of aging portfolio companies, and California-heavy portfolios ‒ particularly in tech, software and life sciences ‒ are no exception. While exit activity is improving, current paths to liquidity are more varied than in prior cycles. Three themes are prominent.

• Continuation vehicles: single-asset continuation funds and GP-led secondaries have become mainstream tools rather than perceived “last resorts.” Where valuation gaps remain or where sponsors see a clear path to improved operating performance over the next 18–36 months, structured liquidity should be a common alternative to a near-term sale.
• Sponsor-to-sponsor transactions: in a still-selective environment, sponsors are increasingly selling portfolio companies to other sponsors. In these transactions, sponsor buyers are typically underwriting a defined operating plan, rather than basing valuations on multiple expansion or market momentum.
• Capital-structure discipline: despite the recent press, private credit remains a critical component of the deal financing landscape, but sponsors are approaching leverage and covenants with greater discipline. Highly levered capital structures ‒ particularly in recurring-revenue software businesses that are prevalent in California ‒ are being thoroughly stress-tested against downside scenarios.

For California-based companies considering an exit, preparation is increasingly determinative. Robust quality-of-earnings analysis, a clear understanding of customer concentration risk and defensible go-to-market metrics will materially enhance the likelihood of a successful sale.

Regulatory risk remains central to deal terms

Even where regulatory clearance is ultimately expected, process risk continues to shape deal negotiations. Parties are allocating antitrust and regulatory risk with greater specificity, including enhanced co-operation covenants and remedy frameworks. Transactions involving California-based technology, life sciences and consumer-facing companies warrant particular attention to regulatory concerns and potential remedies that regulators may impose early in the deal process.

Privacy and data regulation as a front-end issue

California continues to be at the forefront of privacy enforcement. In particular, the California Privacy Protection Agency (CPPA) has demonstrated a willingness to pursue meaningful penalties for company data practices. As a result, buyers are becoming less inclined to rely on generic indemnities to bridge compliance gaps. Instead, deals are increasingly incorporating bespoke covenants addressing pre-closing remediation, security enhancement roadmaps and, where applicable, modifications to marketing practices. Accordingly, privacy maturity is becoming a differentiating factor in sales processes for California businesses.

Labour mobility and talent retention

California’s statutory restrictions on employee non-competes continues to distinguish it from many other jurisdictions. In California, where talent is frequently the primary asset in a transaction, this legal framework has material implications. Buyers are continuing to assess the enforceability of restrictive covenants, utilising the sale of business exception for non-competes and designing retention frameworks that comply with California law. Confidentiality protections, invention assignment agreements and carefully structured incentive equity arrangements are increasingly central components of transaction planning.

Bottom line for 2026

2026 is well positioned to be a strong year for deal activity. This is particularly true in California, where companies are often at the intersection of AI, software, life sciences and consumer platforms. California’s health and beauty sector is also generating significant deal activity, as strategic acquirers and private equity sponsors target direct-to-consumer brands and clean beauty companies that have leveraged the state’s innovation ecosystem and consumer trends to build national and global customers. Buyers in these transactions are placing particular emphasis on brand authenticity, digital customer acquisition strategies, and regulatory compliance with California’s increasingly stringent cosmetics safety and labelling requirements, including the California Toxic-Free Cosmetics Act. In the California deal environment, disciplined diligence, credible regulatory positioning and resilient financing structures will separate successful processes from stalled ones.

Life sciences

Overview of the California life sciences M&A market

California’s life sciences sector continues to be one of the most active M&A markets in the USA, reflecting the state’s concentration of biotechnology, pharmaceutical, diagnostics, and medtech companies. At the same time, the deal environment is evolving as regulatory scrutiny and market dynamics reshape transaction structures and execution.

California remains a global hub for biotechnology and pharmaceutical innovation, with cities such as San Francisco, San Diego, and Los Angeles driving deal activity across therapeutics, diagnostics, and research technologies. A defining characteristic of California’s life sciences M&A market is the scale of capital flowing into the sector. According to Biocom's California 2025 Life Science Economic Impact Report, California-based life sciences companies attracted USD63.1 billion in investment in 2024, with corporate M&A accounting for roughly two-thirds of life sciences investment activity in the state.

Drivers of life sciences M&A activity

Industry data suggests life sciences M&A has regained momentum following uncertainty after a COVID-induced peak in 2021. Large pharmaceutical companies continue to pursue acquisitions to replenish drug pipelines and access innovative technologies developed by smaller biotech companies. Recent market analyses show that deal making accelerated in the latter part of 2025, with average deal sizes increasing significantly year-over-year as buyers focused on acquiring later-stage or de-risked assets, including companies with products further along in clinical development. 

California-based companies are frequently at the centre of strategic acquisitions and M&A transactions in the life sciences sector due to the state’s ecosystem of venture-backed biotechnology firms and university-driven research. Biotechnology, pharmaceutical, and medtech companies each represent approximately one-third of life sciences deal activity globally, highlighting the breadth of subsectors generating acquisition opportunities. Strategic buyers continue to derisk development stage acquisitions through significant shifting of value to future milestones in private deals or contingent value rights in public deals. Private equity firms also remain active participants, accounting for roughly one-quarter of sector deal value in recent years, particularly in healthcare technology, diagnostics, and life sciences services. In California, venture investors have increasingly concentrated capital in later-stage companies, favouring fewer but larger transactions as the sector adapts to constrained fundraising.

Regulatory developments

Despite this activity, California’s regulatory environment is becoming an increasingly important consideration for deal makers. Recent legislation has expanded oversight of healthcare transactions involving private capital. In October 2025, Governor Gavin Newsom signed Assembly Bill 1415, which broadens the state’s healthcare transaction review framework to require private equity firms and hedge funds to provide advance notice of certain healthcare transactions to the California Office of Health Care Affordability (OHCA), a state agency monitoring healthcare market costs and competition.

Assembly Bill 1415 took effect in January 2026 and requires private equity firms and hedge funds to provide at least 90 days’ notice prior to closing certain transactions involving healthcare entities or management services organisations. While OHCA review does not grant regulators authority to veto transactions outright, it increases transparency around deal structures and may extend transaction timelines where additional review is required.

These developments reflect a broader national trend toward heightened scrutiny of private investment in healthcare markets and are already influencing deal strategy. Investors and acquirers are increasingly factoring regulatory review timelines into transaction planning and due diligence. In some cases, parties are reassessing transaction structures or approval processes.

Market dynamics influencing exits and deal strategy

Despite these regulatory complexities, California’s life sciences M&A market remains highly active. Strategic acquirers continue to seek innovative therapies, data-driven clinical tools, and enabling technologies that can accelerate drug development and commercialisation. Acquisition activity is also being driven by several industry dynamics, including pharmaceutical companies seeking to offset the impact of an expected “patent cliff” affecting roughly 190 drugs projected to lose patent or regulatory exclusivity by 2030, as well as growing interest in artificial intelligence-enabled research tools and targeted therapeutic platforms such as oncology and metabolic treatments.

At the same time, venture-backed biotech companies facing capital constraints may view strategic sales as an attractive path to liquidity, particularly where large pharmaceutical companies are seeking targeted acquisitions to address looming patent expirations and pipeline gaps. In that environment, corporate M&A has increasingly served as an exit pathway for start-ups facing a more challenging funding environment and limited public market opportunities.

California will likely remain a focal point for life sciences deal making in the years ahead. California’s concentration of scientific aptitude, venture capital, and leading research institutions continues to produce acquisition targets at every stage of development. Even as deal activity remains strong, evolving regulatory oversight is reshaping the practical realities of completing life sciences transactions in the state, prompting investors to adopt more disciplined timelines and transaction structures as they navigate an increasingly complex M&A landscape.

Entertainment, sports, and media

Overview of California entertainment, sports and media M&A market

California remains a leading hub of US entertainment, sports and media deal making, reflecting its high concentration of talent, content owners, distributors and sports properties. In 2026, transactions will focus on control of premium intellectual property, content monetisation opportunities and direct audience reach, alongside continued scale considerations. Private equity (including private credit) and institutional capital will continue to play a central role in deal structures and competitive dynamics.

Drivers of entertainment and media M&A activity

Consolidation remains a significant driver of entertainment and media M&A. Transformative deals, including the Paramount-Skydance combination and Paramount’s anticipated acquisition of Warner Bros. Discovery (WBD), reflect a push to build scaled platforms with deeper libraries, broader distribution and more durable monetisation models.

This activity is unfolding amid increased regulatory attention in California. In February 2026, Attorney General Rob Bonta called for a “full and robust review” of the Paramount-WBD deal, suggesting potential impacts on deal timing, structuring and execution not only for the Paramount-WBD deal, but also for large-scale media consolidations with California ties.

Simultaneously, media companies are reconfiguring their portfolios by separating higher-growth assets from more mature or declining businesses, such as linear television assets. Comcast’s spin-off of a portfolio of cable networks into publicly traded Versant, for example, reflects a shift toward isolating and unlocking value across distinct business lines. These separations will likely create additional opportunities for follow‑on M&A, divestments, joint ventures and strategic transactions.

Trends in sports M&A

In the sports sector, private equity and institutional investors will continue to play a growing role in ownership and financing structures. Capital is flowing into all corners of the sports landscape, including legacy sports assets and emerging and women’s sports properties with strong growth potential and expanding media value. League One Volleyball, for example, raised USD100 million in a funding round led by Atwater Capital alongside other institutional investors. Newer platforms such as Unrivaled have also attracted significant venture capital, and expansion activity in leagues such as the National Women’s Soccer League ‒ where new franchises have commanded record expansion fees ‒ reflects investor demand for scalable sports assets across stages of development.

The market for sports media rights is also undergoing rapid change. Traditional broadcast models are being supplemented, and in some cases displaced, by direct-to-consumer and streaming arrangements, with platforms competing aggressively for premium rights. Major rights packages now in effect ‒ such as the NBA’s multi-platform agreements spanning ABC/ESPN, NBC/Peacock and Prime Video, and Paramount’s long-term UFC deal ‒ demonstrate how live sports are being treated as strategic assets for subscriber growth, advertising and platform differentiation.

Sports transactions are also intersecting more closely with adjacent sectors, including media production, data analytics and live entertainment infrastructure, as stadiums and related developments are positioned as multi-use entertainment destinations.

Trends in music M&A

Catalog acquisitions continue to be a major driver of music M&A, though the structure of those transactions is evolving. Major record labels and publishers are increasingly partnering with private equity and institutional investors, using joint ventures and investment platforms to scale acquisition strategies. This approach is reflected in Warner Music Group’s joint venture with Bain Capital to acquire up to USD1.2 billion of music catalogs and Sony Music Group’s partnership with GIC (reported to target USD2-3 billion).

Music assets are also being assessed as part of wider intellectual property ecosystems, with value driven by synchronisation, licensing and cross-platform monetisation. Universal Music Group’s partnership with WTSL reveals a focus on expanding music-related IP into film, television, fashion, consumer products and branded experiences. WBD’s spin-off of its music publishing assets into a joint venture backed by a consortium of private equity investors also highlights the importance of broader exploitation and active management of music rights. This emphasis on multi-channel monetisation remains a key factor in how assets are valued and structured in current transactions.

Conclusion

California’s corporate M&A market in 2026 reflects the breadth and vibrancy of the state’s economy. Across each of the sectors examined in this article ‒ venture capital and AI, M&A and private equity, life sciences, and entertainment, sports, and media ‒ a set of common themes emerges. Capital continues to flow toward innovation, but with greater discipline and selectivity. Regulatory complexity, whether at the federal or state level, is no longer a background consideration but a front-end driver of deal strategy, structure, and timing. And the pathways to liquidity and exit are diversifying, as market participants adapt to an environment in which traditional routes ‒ the IPO, the straightforward strategic sale ‒ are complemented by alternative structures like continuation vehicles, structured secondaries, sponsor-to-sponsor transactions, and strategic option deals.

For deal makers and their advisors, the California market rewards preparation, sector expertise, and a clear-eyed understanding of the regulatory and commercial landscape. Companies that can demonstrate defensible technology, regulatory readiness, and operational resilience will continue to attract premium valuations. Those that cannot will face longer processes, tougher negotiations, and greater valuation pressure. As the state’s leading industries continue to evolve, California will remain at the centre of the most consequential M&A activity in the United States.